Veloxis' Tacrolimus Clears FDA For Narrower Population Following Court Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Envarsus XR, a once-daily version of the immunosuppressant, is approved for kidney transplant patients seeking to convert from twice-daily formulations; a claim for use in newly transplanted, 'de novo' patients was blocked by Astellas' three-year exclusivity on Astagraf.
You may also be interested in...
FDA Staff ‘Literally’ Up At Night Deciding 3-Year Exclusivity Requests
More sponsors are submitting applications around the same time requiring the agency to make complicated decisions about exclusivity and whether approval of subsequent applications is barred, FDA attorney says.
Keeping Track Of The US FDA's Final Approvals Of 2018
A roundup of the US FDA's drug approvals in the final weeks of 2018.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.